Cleo Diagnostics advances ovarian cancer detection with Bio-Techne's Ella ELISA platform. The innovative blood test uses the CXCL10 biomarker to distinguish between benign and malignant growths with 90% accuracy in early-stage detection. This breakthrough technology represents a significant improvement over current diagnostic methods, which only detect 50% of early-stage cancers. The company is preparing for FDA 510(k) submission using approximately 500 blood samples for validation. Developed through 15 years of research at the Hudson Institute of Medical Research, this test could revolutionize ovarian cancer screening by providing a more precise and accessible diagnostic tool for laboratories worldwide. The potential for early and accurate detection could dramatically improve patient outcomes and survival rates in ovarian cancer treatment.
